

Evaluation of a Commercial Culture-free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison with an Anti-RBD ELISA Assay

Jesse Papenburg MD MSc^{a,b,c,d†}, Matthew P. Cheng MDCM^{b,c,e†}, Rachel Corsini MSc^c, Chelsea Caya MScPH^c, Emelissa Mendoza^f, Kathy Manguiat^f, Heidi Wood^f, Michael A. Drebot^f, Gerasimos Zaharatos^{b,c}, Renée Bazin PhD^g, Guillaume Beaudoin-Bussi res BSc^{h,i}, J r mie Pr vost BSc^{h,i}, Andr s Finzi PhD^{h,i}, Momar Ndao DVM PhD^{c,j,k}, Cedric P Yansouni MD^{b,c,e,k#}

^aDivision of Pediatric Infectious Diseases, Department of Pediatrics, Montreal Children's Hospital, Montreal, Quebec, Canada

^bDivision of Microbiology, Department of Clinical Laboratory Medicine, Optilab Montreal - McGill University Health Centre, Montreal, Quebec, Canada

^cMcGill Interdisciplinary Initiative in Infection and Immunity, Montreal, Quebec, Canada

^dDepartment of Epidemiology, Biostatistics, and Occupational Health, School of Population and Global Health, McGill University, Montreal, Quebec, Canada

^eDivision of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada

^fZoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada

^gAffaires M dicales et Innovation, H ma-Qu bec, Qu bec, Quebec, Canada

^hD partement de Microbiologie, Infectiologie et Immunologie, Universit  de Montr al, Montreal, Quebec, Canada

ⁱMontreal, Quebec, Canada

^jMontreal, Quebec, Canada

^kMontreal, Quebec, Canada

[#]Montreal, Quebec, Canada

[†]These authors contributed equally to this work

^{Correspondence:} Dr. Jesse Papenburg, jpapenburg@montrealchildrens.org

^{Conflict of interest:} The authors have nothing to disclose.

^{Disclaimer:} This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 23 ⁱCentre de Recherche du CHUM, Montreal, Quebec, Canada
- 24 ^jNational Reference Centre for Parasitology, Montreal, Quebec, Canada
- 25 ^kJ.D. MacLean Centre for Tropical Diseases, McGill University, Montreal, Quebec, Canada
- 26 [†] These authors contributed equally to this manuscript
- 27 Running Title: Evaluation of cPass SARS-CoV-2 assay
- 28 Tables: 2
- 29 Figures: 4
- 30 Word count text: 2925
- 31 Word count abstract: 200

Funding

C.P.Y and J. Papenburg hold a “Chercheur-boursier clinicien” career award from the Fonds de recherche du Québec – Santé (FRQS). This work was partially supported by le Ministère de l’Économie et de l’Innovation du Québec (Program de soutien aux organismes de recherche et d’innovation), by the Fondation du CHUM, and by the Canadian Institutes of Health Research (via the COVID-19 Immunity Task Force) to A.F. A.F. is the recipient of a Canada Research Chair on Retroviral Entry (RCHS0235 950-232424). G.B.B, and J. Prévost are supported by CIHR fellowships.

cPass kits were provided in kind by Genscript.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Potential conflicts of interest

J. Papenburg reports grants from MedImmune, grants from Sanofi Pasteur, grants and personal fees from Seegene, grants and personal fees from Janssen Pharmaceutical, grants and personal fees from AbbVie, outside the submitted work. MPC reports personal fees from GEn1E Lifesciences (as a member of the scientific advisory board) and personal fees from nplex biosciences (as a member of the scientific advisory board), both outside the submitted work.

#Correspondence to:

Cédric Yansouni, MD, J.D. MacLean Centre for Tropical Diseases, Divisions of Infectious Diseases and Medical Microbiology, McGill University Health Centre, 1001 Décarie Blvd., Room EM3.3242, Montreal, Qc., Canada H4A 3J1, Email: cedric.yansouni@mcgill.ca

ABSTRACT

Background: SARS-CoV-2 surrogate neutralization assays that bypass the need for viral culture offer substantial advantages regarding throughput and cost. The cPass SARS-CoV-2 Neutralization Antibody Detection Kit (Genscript) is the first such commercially available assay, detecting antibodies that block RBD/ACE-2 interaction. We aimed to evaluate cPass to inform its use and assess its added value compared to anti-RBD ELISA assays.

Methods: Serum reference panels were used to compare cPass to plaque-reduction neutralization test (PRNT) and a pseudotyped lentiviral neutralization assay for detection of neutralizing antibodies. We assessed the correlation of cPass with an ELISA detecting anti-RBD IgG, IgM, and IgA antibodies at a single timepoint and across intervals from onset of symptoms of SARS-CoV-2 infection.

Results: Compared to PRNT-50%, cPass had 100% sensitivity (95%CI 82-100) and 95% specificity (76-100). Sensitivity was also very high compared to the pseudotyped lentiviral neutralization assay, but specificity was lower, ranging from 17-70%. Highest agreement between cPass and ELISA was for anti-RBD IgG ($r=0.851$ at 0-6 weeks; $r=0.798$ at > 6 weeks). Anti-RBD IgG diagnostic accuracy for detection of neutralizing antibodies was essentially identical to that of cPass.

Conclusions: The added value of cPass compared to an IgG anti-RBD ELISA was not supported by these results.

Key Words: “SARS-CoV-2”, “COVID-19”, “Diagnosis”, “Serology”, “ELISA”, “Neutralization Test”, “Neutralizing Antibodies”, “Immunity”

78 INTRODUCTION

79 Use cases for serological testing for prior exposure to *Severe acute respiratory*
 80 *syndrome-related coronavirus-2* (SARS-CoV-2) have been reviewed in detail (1, 2). Despite a
 81 rapid increase in the number and availability of serological assays detecting SARS-CoV-2
 82 antibodies, critical knowledge gaps remain regarding the magnitude and kinetics of the
 83 correlation between results of these assays and the presence of neutralizing antibodies.

84 Only a subset of antibodies against a specific antigen can neutralize viral replication.
 85 Assays that measure neutralizing antibody levels, such as plaque reduction neutralization
 86 tests (PRNT) and microneutralization methods, provide essential data, both for the validation
 87 of candidate diagnostic tests and to define serological correlates of immunity. These
 88 functional cell-based assays of SARS-CoV-2 neutralization can only be performed in a
 89 Biosafety Level 3 (BSL-3) laboratory, which is labour-intensive, costly, and severely limits
 90 testing throughput. Pseudotyped viruses have been developed that incorporate the Spike
 91 protein of SARS-CoV-2 and can be cultivated in BSL-2 conditions (3). Assays incorporating
 92 such pseudotyped viruses provide a functional assessment of the host neutralizing antibody
 93 responses as an alternative to using the wild-type virus (4-7). By contrast, surrogates of
 94 neutralization that bypass the need for viral culture would offer substantial advantages in
 95 terms of throughput, cost, and scalability. At least one direct ELISA assay detecting
 96 antibodies to the whole Spike protein has received regulatory approval in Europe for
 97 assessment of neutralizing antibodies (8). Further, several groups have proposed blocking
 98 assays, leveraging different signal detection methods to quantify the presence of host
 99 antibodies that can block the interaction of the SARS-CoV-2 Spike protein with human ACE-
 100 2 receptor (9-12).

On 6 Nov 2020, the FDA issued an emergency use authorization (EUA) for the cPass SARS-CoV-2 Neutralization Antibody Detection Kit (cPass; Genscript, Piscataway, NJ)(13), which is the first such surrogate neutralization assay to be commercially available. The cPass uses a blocking ELISA format with human ACE-2 receptor molecules coated on an ELISA plate (9, 14). Human sera pre-incubated with labelled epitopes of the receptor binding domain (RBD on S1 proteins) are then transferred to the plate. This blocking ELISA serves as a surrogate assay to inform on the capacity of human sera to block the interaction between the Spike fusion protein (through its RBD) and its cellular receptor ACE-2.

Thus, we aimed to inform the use of the cPass and assess its added value compared to laboratory-developed anti-RBD ELISA assays by performing an evaluation using a variety of well characterised specimens. A number of reference panels were utilized to allow an understanding of the ability of the cPass assay to detect significant titres of neutralizing antibodies assessed by culture-based reference methods. We compared cPass to PRNT and to a pseudotyped virus neutralization assay. We also sought to describe the correlation of cPass with a laboratory-developed indirect ELISA detecting anti-RBD IgG, IgM, and IgA antibodies at a single timepoint and across different timeframes among specimens collected at a known interval from onset of symptoms of SARS-CoV-2 infection.

118 **METHODS**

119 **Ethics**

120 All work was conducted in accordance with the Declaration of Helsinki in terms of
 121 informed consent and approval by an appropriate institutional board. Convalescent plasmas
 122 were obtained from donors who consented to participate in this research project at Héma-
 123 Québec, the agency responsible for blood supply in Quebec, Canada, (Research Ethics Board
 124 [REB] # 2020-004) and the Centre de Recherche du Centre Hospitalier de l'Université de
 125 Montréal (CR-CHUM) (REB # 19.381). The donors met all donor eligibility criteria:
 126 previous confirmed COVID-19 infection and complete resolution of symptoms for at least 14
 127 days. At the Research Institute of the McGill University Health Centre (RI-MUHC), where
 128 cPass testing was performed, an REB exemption was granted on the basis that this work was
 129 considered to be a laboratory quality improvement project with no risk to participants.

130 **Source of specimens tested**

131 We assembled several well-characterised SARS-CoV-2 specimen panels to assess the
 132 performance characteristics of the cPass culture-free neutralization antibody detection kit
 133 (Table 1). These panels included: the Public Health Agency of Canada's National
 134 Microbiology Laboratory SARS-CoV-2 panel of serological samples from COVID-19
 135 patients, healthy individuals, as well as patients non-SARS-CoV-2 infections (Supplemental
 136 Table 1); the World Health Organization's "First WHO International Reference Panel for
 137 anti-SARS-CoV-2 immunoglobulin" (NIBSC code 20/268) (15); and two separate curated
 138 panels from Héma-Québec and CR-CHUM. The later panels comprised convalescent plasma
 139 donors with either longitudinal or single timepoint follow-up after SARS-CoV-2 diagnosis.
 140 Diagnosis of infection was either via nucleic acid amplification (NAAT), or by a case-
 141 definition requiring symptomatic disease and contact with a NAAT-confirmed individual.

Culture-free neutralization antibody detection assay (cPass)

All the specimens, including positive and negative controls provided with the kit, were processed according to the manufacturer's instructions that included a 10X dilution factor of the primary specimen. To assure the validity of the results, all controls met the manufacturer's requirements. All specimens and controls were tested in triplicate and the percentage of inhibition calculation was based on the mean of OD for each triplicate. A cut-off of 30% for SARS-CoV-2 neutralizing antibody detection was used to determine the presence of neutralizing antibodies, based on the manufacturer's instructions for use. Kits were provided in kind by GenScript, but the manufacturer had no role in the design of the study, analysis of the data, or decision to submit the manuscript for publication.

Detection of neutralizing antibodies by culture-based reference methods

Neutralizing antibodies were detected via either assessment of plaque reduction neutralization titres using wild-type SARS-CoV-2, or by determining the neutralization half-maximal inhibitory dilution (PLV ID₅₀) or the neutralization 80% inhibitory dilution (PLV ID₈₀) of pseudotyped lentiviral vector (16).

Assessment of plaque-reduction neutralization using wild-type SARS-CoV-2 was performed at the Public Health Agency of Canada's National Reference Laboratory for Microbiology. Briefly, serological specimens were diluted 2-fold from 1:20 to 1:640 in DMEM supplemented with 2% FBS and challenged with 50 plaque forming units (PFU) of SARS-CoV-2 (hCoV-19/Canada/ON_ON-VIDO-01-2/2020, EPI_ISL_425177), which were titrated by plaque assay (17). After 1 hour of incubation at 37°C and 5% CO₂, the sera-virus mixtures were added to 12-well plates containing Vero E6 cells at 90% to 100% confluence and incubated at 37°C and 5% CO₂ for 1 hour. After adsorption, a liquid overlay comprising 1.5% carboxymethylcellulose diluted in MEM supplemented with 4% FBS, L-glutamine,

non-essential amino acids, and sodium bicarbonate was added to each well and plates were incubated at 37°C and 5% CO₂ for 72 hours. The liquid overlay was removed, and cells were fixed with 10% neutral-buffered formalin for 1 hour at room temperature. The monolayers were stained with 0.5% crystal violet for 10 minutes and washed with 20% ethanol. Plaques were enumerated and compared to controls. The highest serum dilution resulting in 50% and 90% reduction in plaques compared with controls were defined as the PRNT-50 and PRNT-90 endpoint titres, respectively. PRNT-50 titres and PRNT-90 titres $\geq 1:20$ were considered positive for SARS-CoV-2 neutralizing antibodies.

Pseudoviral neutralization testing was performed as previously described (16). Briefly, target cells were infected with single-round luciferase-expressing lentiviral particles. HEK 293T cells were transfected by the calcium phosphate method with the lentiviral vector pNL4.3 R-E- Luc (NIH AIDS Reagent Program) and a plasmid encoding for SARS- CoV-2 Spike at a ratio of 5:4. Two days post-transfection, cell supernatants were harvested and stored at -80°C until use. 293T-ACE2 target cells were seeded at a density of 1×10^4 cells/well in 96-well luminometer-compatible tissue culture plates (Perkin Elmer) 24h before infection. Recombinant viruses in a final volume of 100 μ L were incubated with the indicated sera dilutions (1/50; 1/250; 1/1250; 1/6250; 1/31250) for 1h at 37°C and were then added to the target cells followed by incubation for 48h at 37°C; cells were lysed by the addition of 30 μ L of passive lysis buffer (Promega) followed by one freeze-thaw cycle. An LB942 TriStar luminometer (Berthold Technologies) was used to measure the luciferase activity of each well after the addition of 100 μ L of luciferin buffer (15mM MgSO₄, 15mM KPO₄ [pH 7.8], 1mM ATP, and 1mM dithiothreitol) and 50 μ L of 1mM d-luciferin potassium salt (ThermoFisher Scientific). The neutralization half-maximal inhibitory dilution (ID₅₀) or the neutralization 80% inhibitory dilution (ID₈₀) represents the sera dilution to inhibit 50% or

80% of the infection of 293T-ACE2 cells by recombinant viruses bearing the indicated surface glycoproteins.

Indirect antiRBD ELISA assays

Specimens were analysed with a laboratory-developed indirect ELISA detecting anti-RBD IgG, IgM, and IgA as previously described (16).

Statistical analysis

The diagnostic accuracy of the cPass surrogate viral neutralization assay was estimated compared to different reference standards (WT PRNT-50; WT PRNT-90; PLV ID50; PLV ID80, Live Virus (CPE), and VSV-PV). Sensitivities and specificities are presented with 95% confidence intervals (95% CI). The effect of varying the cut-off value (i.e., % inhibition of RBD-ACE2 binding) for cPass positivity on the diagnostic accuracy of the cPass against a PLV PRNT-50 reference standard was investigated using a receiver operating characteristic (ROC) curve. The association between cPass % inhibition and results obtained using laboratory-developed ELISA detecting anti-S-RBD IgG, IgM, and IgA are presented in scatterplots with the strength of these associations informed by Pearson correlation. Lastly, among specimens with a known interval from onset of SARS-CoV-2 infection symptoms (n=79), spaghetti plots were created to investigate any change in signal over time for the cPass and direct anti-S-RBD ELISA with statistical significance assessed using the Wilcoxon matched-pairs signed-rank test ($p < 0.05$ denoted by *). Statistical analyses were performed using R version 3.5.2 (R Core Team, Vienna, Austria).

RESULTS

Diagnostic accuracy for the detection of anti-SARS-CoV-2 neutralizing antibodies, and the impact of using different reference standards

Table 1 shows the estimated diagnostic accuracy of the GenScript cPass neutralization antibody detection assay among well characterised specimen panels, according to different reference standards. Among various reference standards, results from the same PLV ID50 assay were available for all panels except the WHO panel, and this was used to estimate aggregate diagnostic accuracy values across several panels.

Overall, cPass had very high sensitivity and specificity compared to the reference standard of a 50% plaque reduction neutralization using SARS-CoV-2 viral culture (WT PRNT-50). This remained the case whether a cut-off titre of 1:20 or 1:50 was used [sensitivity 100% (95%CI 82-100) for both cut-offs, specificity 95% (95%CI 76-100) and 91% (95%CI 71-99), respectively]. Sensitivity remained very high compared to the reference standard of a neutralization half-maximal inhibitory dilution using a validated pseudotyped lentiviral vector neutralization assay (PLV ID50) with a cut-off titre of 1:50, but specificity was lower than that compared to WT PRNT-50, ranging from 17-70% (Table 1).

The effect of cut-off values on the diagnostic accuracy of the GenScript cPass assay is shown in Figure 1. A receiver operating characteristic (ROC) curve using the reference standard of PLV ID50 yielded an area under the ROC curve of 0.802.

Effect of serial dilution on the accuracy for detecting sera with positive PRNT-90 titres

Against the most stringent reference standard of 90% plaque reduction neutralization using SARS-CoV-2 viral culture (WT PRNT-90), estimated specificity was reduced compared to WT PRNT-50. Specificity remained similar whether a cut-off WT PRNT-90 titre for positivity of 1:20 or 1:50 was used [61% (95%CI 42-77) and 57% (95%CI 39-74),

respectively] (Table 1). We performed serial dilution of the 16 primary specimens from the National Microbiology Laboratory Panel with WT PRNT-50 titres $\geq 1:20$ to determine whether we could establish a dilution that increased specificity for detecting those with WT PRNT-90 titres $\geq 1:20$ without sacrificing sensitivity. A 50-fold dilution of specimens with positive WT PRNT-50 titres increased specificity for those with positive WT PRNT-90 titres from 11% (95%CI 0-48) to 100% (95%CI 66-100), with one missed PRNT-90 positive specimen. Results are summarised in Figure 2.

Correlation of the GenScript cPass assay with anti-RBD ELISA, and signal variation according to time interval since onset of SARS-CoV-2 infection symptoms.

Results obtained with cPass were compared to those obtained using laboratory-developed ELISA detecting anti-RBD IgG, IgM, and IgA to assess whether the cPass yields complementary information (Figure 3). Highest agreement between cPass percent inhibition of RBD-ACE2 binding and ELISA area under the curve (AUC) was seen for anti-RBD IgG ($r=0.851$ at 0-6 weeks; $r=0.798$ at > 6 weeks). The diagnostic accuracy of categorical anti-RBD IgG results for the detection of SARS-CoV-2 neutralizing antibodies was essentially identical to that observed with the cPass for all panels and reference standards (Table 2).

Among paired specimens from the same individual collected at a known interval from SARS-CoV-2 diagnosis, aggregate results of both cPass and direct anti-RBD IgG ELISA did not change between 6 weeks and 10 weeks after diagnosis ($p=1.00$ and 0.104 , respectively, by the Wilcoxon signed rank test) (Figure 4). In contrast, optical densities decreased significantly over the same timeframe for direct anti-RBD IgM ($p=0.0058$) and IgA ($p=0.0012$) ELISA.

259 DISCUSSION

260 Rapid and high throughput surrogates for PRNT or pseudovirus neutralization assays
 261 that bypass the need for cell culture are awaited with the belief that they will offer additional
 262 information to that from standard direct immunoassays, such as a higher specificity for
 263 neutralizing antibodies. The cPass SARS-CoV-2 Neutralization Antibody Detection Kit
 264 (cPass) is the first such assay to be commercially available and to receive FDA EUA in the
 265 U.S. An evaluation of a cPass prototype, using a cut-off value of 20% inhibition, found that it
 266 could provide a high-throughput screening tool for confirmatory PRNT testing (18). The
 267 results of the current evaluation support the ability for cPass to detect neutralizing antibodies
 268 to SARS-CoV-2, and extend our understanding of how cPass results compare to those
 269 obtained with non-blocking anti-RBD ELISA among varied well characterised specimen
 270 panels.

271 The estimated sensitivity of cPass for detection of anti-SARS-CoV-2 neutralizing
 272 antibodies was consistently very high, regardless of the reference standard technique or cut-
 273 off titre for positivity. Despite the fact that several groups have described anti-SARS-CoV-2
 274 neutralizing antibodies that target non-RBD epitopes (19-21), our results do not suggest that
 275 this assay targeting only RBD-ACE2 blockade would miss a substantial proportion of
 276 patients with neutralizing antibodies identified by a functional cell-culture-based reference
 277 standard. This may be the case because neutralizing antibodies to non-RBD epitopes usually
 278 occur concomitantly with anti-RBD neutralizing antibodies, instead of in isolation (19-21).
 279 This requires elucidation.

280 By contrast, estimates of the specificity of cPass for the detection of anti-SARS-CoV-
 281 2 neutralizing antibodies were highly contingent of the reference standard used. There was
 282 near-perfect negative agreement with WT PRNT-50 using a cut-off titre of either 1:20 or 1:50

[95% (95%CI 76-100) and 91% (95%CI 71-99), respectively]. However, negative agreement was much lower when cPass was compared to either PLV ID50 or WT PRNT-90 (Table 1). Our data raise the unresolved question of which reference technique (i.e., wild-type or pseudotyped live viral culture), level of stringency (e.g., 50% inhibition of infection vs 80%, 90%, etc), and cut-off titre (e.g., 1:20 vs 1:50) best represent serocorrelates of protection to SARS-CoV-2, or other relevant applications such as the screening of sera for use in convalescent plasma trials. Moreover, protocols can vary widely for the same technique across different laboratories, requiring caution in the interpretation of these and other data (22). In the current manuscript, PLV ID50 with a cut-off titre of 1:50 was used as the overall comparator because it was the technique applied to all available specimen panels. Our results must be interpreted in context with this potential source of bias. However, we note that this technique has been widely employed by other groups and as such offers a high degree of generalizability with other results (23, 24).

The cPass assay detected all specimens with positive WT PRNT-90 titres, with a significant proportion of false positives (Figure 2). This suggests that, within the panel tested, the functional assessment of RBD-ACE2 blocking antibodies did not miss specimens that may have included neutralizing antibodies to other targets in addition to those against RBD. A 50-fold dilution of the 16 primary specimens with WT PRNT-50 titres $\geq 1:20$ increased specificity for detecting those with WT PRNT-90 titres $\geq 1:20$ from 11% (95% CI 0-48) to 100% (95% CI 66-100). This may represent a useful approach for using the cPass assay to identify blood specimens with positive WT PRNT-90 titres, which has been proposed as a desirable characteristic for sera used in convalescent plasma trials by some regulatory agencies.

Finally, results of the cPass assay are best correlated with those of a laboratory-developed indirect anti-RBD ELISA detecting IgG, both at a single timepoint (Table 2, Figure 3) and across time among paired specimens from the same individual collected at a known interval from symptoms onset (Figure 4). The fact that results of cPass and anti-RBD IgG remained stable between 6 and 10 weeks post-symptom onset, while optical densities decreased significantly over the same timeframe for anti-RBD IgM and IgA ELISA is potentially concerning given recent work suggesting a major role of IgM and IgA in the neutralizing activity of convalescent plasma against SARS-CoV-2 (25-28). The observed trend toward lower specificity at later timepoints among convalescent plasma donors with longitudinal follow-up (i.e. [60% (95% CI 15-95)] at 6 weeks vs [17% (95% CI 0-64)] at 10 weeks) may thus be related to loss of neutralizing IgM (Table 1). In addition, specificity of the cPass may be affected by the possibility that part of the inhibition of binding in the cPass assay could be due to steric hindrance by the abundant anti-Spike antibodies of the IgG isotype rather than by true neutralization (as occurs in vivo).

CONCLUSIONS

The results of the current evaluation demonstrate the ability of cPass to detect blood specimens with anti-SARS-CoV-2 neutralizing antibodies, but they do not support a clear added value of cPass compared to a laboratory-developed indirect anti-RBD ELISA detecting IgG antibodies. Whether this is also the case for commercially-available direct anti-RBD ELISAs deserves further investigation.

328 **ACKNOWLEDGEMENTS**

329 We thank the convalescent plasma donors who participated in this study; the Héma-
 330 Québec team involved in convalescent donor recruitment and plasma collection; the staff
 331 members of the CRCHUM BSL3 Platform for technical assistance; Stefan Pöhlmann (Georg-
 332 August University, Germany) for the plasmid coding for SARS-CoV-2 S.

REFERENCES

1. Cheng MP, Yansouni CP, Basta NE, Desjardins M, Kanjilal S, Paquette K, Caya C, Semret M, Quach C, Libman M, Mazzola L, Sacks JA, Dittrich S, Papenburg J. 2020. Serodiagnostics for Severe Acute Respiratory Syndrome-Related Coronavirus 2 : A Narrative Review. *Ann Intern Med* 173:450-460.
2. Van Caesele P, Bailey D, Forgie SE, Dingle TC, Krajden M. 2020. SARS-CoV-2 (COVID-19) serology: implications for clinical practice, laboratory medicine and public health. *Cmaj* 192:E973-e979.
3. Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, Chu HY, Tortorici MA, Veelsler D, Murphy M, Pettie D, King NP, Balazs AB, Bloom JD. 2020. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. *Viruses* 12.
4. Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, Zhang L, Nie L, Qin H, Wang M, Lu Q, Li X, Sun Q, Liu J, Fan C, Huang W, Xu M, Wang Y. 2020. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. *Emerg Microbes Infect* 9:680-686.
5. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, Jiang K, Arunkumar GA, Jurczyszak D, Polanco J, Bermudez-Gonzalez M, Kleiner G, Aydililo T, Miorin L, Fierer DS, Lugo LA, Kojic EM, Stoeve J, Liu STH, Cunningham-Rundles C, Felgner PL, Moran T, García-Sastre A, Caplivski D, Cheng AC, Kedzierska K, Vapalahti O, Hepojoki JM, Simon V, Krammer F. 2020. A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med* 26:1033-1036.

6. Li Q, Liu Q, Huang W, Li X, Wang Y. 2018. Current status on the development of pseudoviruses for enveloped viruses. *Rev Med Virol* 28.
7. Hyseni I, Molesti E, Benincasa L, Piu P, Casa E, Temperton NJ, Manenti A, Montomoli E. 2020. Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays. *Viruses* 12.
8. DiaSorin S.p.A. 2020. Liaison(R) SARS-CoV-2 S1/S2 IgG Brochure -A quantitative assay with correlation to neutralizing antibodies.6.
9. Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, Hu Z, Chen VC, Young BE, Sia WR, Tan YJ, Foo R, Yi Y, Lye DC, Anderson DE, Wang LF. 2020. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. *Nat Biotechnol* 38:1073-1078.
10. Muruato AE, Fontes-Garfias CR, Ren P, Garcia-Blanco MA, Menachery VD, Xie X, Shi PY. 2020. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. *Nat Commun* 11:4059.
11. Danh K, Karp DG, Robinson PV, Seftel D, Stone M, Simmons G, Bagri A, Schreiber M, Buser A, Holbro A, Battegay M, Corash LM, Hanson C, Tsai CT. 2020. Detection of SARS-CoV-2 neutralizing antibodies with a cell-free PCR assay. *medRxiv* doi:10.1101/2020.05.28.20105692.
12. Abe KT, Li Z, Samson R, Samavarchi-Tehrani P, Valcourt EJ, Wood H, Budylowski P, Dupuis AP, 2nd, Girardin RC, Rathod B, Wang JH, Barrios-Rodiles M, Colwill K, McGeer AJ, Mubareka S, Gommerman JL, Durocher Y, Ostrowski M, McDonough KA, Drebot MA, Drews SJ, Rini JM, Gingras AC. 2020. A simple protein-based surrogate neutralization assay for SARS-CoV-2. *JCI Insight* 5.

13. U.S. Food and Drug Administration (FDA). 2020. Coronavirus (COVID-19) Update: FDA Authorizes First Test that Detects Neutralizing Antibodies from Recent or Prior SARS-CoV-2 Infection.
14. GenScript USA Inc. 2020. cPass(TM) SARS-CoV-2 Neutralization Antibody Detection Kit -Instructions for use.18.
15. The National Institute for Biological Standards and Control (NIBSC). 2020. First WHO International Reference Panel for anti-SARS-CoV-2 immunoglobulin (NIBSC code: 20/268).2.
16. Prévost J, Gasser R, Beaudoin-Bussi res G, Richard J, Duerr R, Laumaea A, Anand SP, Goyette G, Benlarbi M, Ding S, Medjahed H, Lewin A, Perreault J, Tremblay T, Gendron-Lepage G, Gauthier N, Carrier M, Marcoux D, Pich  A, Lavoie M, Benoit A, Loungnarath V, Brochu G, Haddad E, Stacey HD, Miller MS, Desforges M, Talbot PJ, Maule GTG, C  t  M, Therrien C, Serhir B, Bazin R, Roger M, Finzi A. 2020. Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. Cell Rep Med 1:100126.
17. Mendoza EJ, Manguiat K, Wood H, Drebot M. 2020. Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS-CoV-2. Curr Protoc Microbiol 57:ecpmc105.
18. Valcourt EJ, Manguiat K, Robinson A, Chen JC, Dimitrova K, Philipson C, Lamoureux L, McLachlan E, Schiffman Z, Drebot MA, Wood H. 2020. Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Diagn Microbiol Infect Dis 99:115294.
19. Voss WN, Hou YJ, Johnson NV, Kim JE, Delidakis G, Horton AP, Bartzoka F, Paresi CJ, Tanno Y, Abbasi SA, Pickens W, George K, Boutz DR, Towers DM, McDaniel

- JR, Billick D, Goike J, Rowe L, Batra D, Pohl J, Lee J, Gangappa S, Sambhara S, Gadush M, Wang N, Person MD, Iverson BL, Gollihar JD, Dye J, Herbert A, Baric RS, McLellan JS, Georgiou G, Lavinder JJ, Ippolito GC. 2020. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma. bioRxiv doi:10.1101/2020.12.20.423708.
20. Wec AZ, Wrapp D, Herbert AS, Maurer DP, Haslwanter D, Sakharkar M, Jangra RK, Dieterle ME, Lilov A, Huang D, Tse LV, Johnson NV, Hsieh C-L, Wang N, Nett JH, Champney E, Burnina I, Brown M, Lin S, Sinclair M, Johnson C, Pudi S, Bortz R, 3rd, Wirchnianski AS, Laudermilch E, Florez C, Fels JM, O'Brien CM, Graham BS, Nemazee D, Burton DR, Baric RS, Voss JE, Chandran K, Dye JM, McLellan JS, Walker LM. 2020. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science (New York, NY) 369:731-736.
21. Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KY, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y, Shapiro L, Ho DD. 2020. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450-456.
22. Ferrara F, Temperton N. 2018. Pseudotype Neutralization Assays: From Laboratory Bench to Data Analysis. Methods Protoc 1.
23. Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, McGuire J, Clearly S, Furrie E, Greig N, Hay G, Templeton K, Lorenzi JCC, Hatzioannou T, Jenks S, Bieniasz PD. 2020. Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. The Journal of Infectious Diseases doi:10.1093/infdis/jiaa659.

24. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, Ladinsky M, Cho A, Jankovic M, Schaefer-Babajew D, Oliveira TY, Cipolla M, Viant C, Barnes CO, Hurley A, Turroja M, Gordon K, Millard KG, Ramos V, Schmidt F, Weisblum Y, Jha D, Tankelevich M, Yee J, Shimeliovich I, Robbiani DF, Zhao Z, Gazumyan A, Hatzioannou T, Bjorkman PJ, Mehendru S, Bieniasz PD, Caskey M, Nussenzweig MC. 2020. Evolution of Antibody Immunity to SARS-CoV-2. bioRxiv doi:10.1101/2020.11.03.367391:2020.11.03.367391.
25. Gasser R, Cloutier M, Prévost J, Corby F, Ducas E, Ding S, Dussault N, Landry P, Tremblay T, Laforce-Lavoie A, Lewin A, Beaudoin-Bussi res G, Laumaea A, Medjahed H, Larochelle C, Richard J, Dekaban G, Dikeakos J, Bazin R, Finzi A. 2020. Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2. bioRxiv doi:<https://doi.org/10.1101/2020.10.09.333278>.
26. Klingler J, Weiss S, Itri V, Liu X, Oguntuyo KY, Stevens C, Ikegame S, Hung CT, Enyindah-Asonye G, Amanat F, Baine I, Arinsburg S, Bandres JC, Kojic EM, Stoeve J, Jurczyszak D, Bermudez-Gonzalez M, N das A, Liu S, Lee B, Zolla-Pazner S, Hioe CE. 2020. Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. J Infect Dis doi:10.1093/infdis/jiaa784.
27. Beaudoin-Bussi res G, Laumaea A, Anand SP, Pr vost J, Gasser R, Goyette G, Medjahed H, Perreault J, Tremblay T, Lewin A, Gokool L, Morrisseau C, B gin P, Tremblay C, Martel-Laferr re V, Kaufmann DE, Richard J, Bazin R, Finzi A. 2020. Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals. mBio 11:e02590-20.
28. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Cla r L, Quentric P, Fadlallah J, Devilliers H, Ghillani P, Gunn C, Hockett R, Mudumba S, Guihot A, Luyt CE, Mayaux J, Beurton A, Fourati S, Bruel T, Schwartz O, Lacorte JM, Yssel H, Parizot

455 C, Dorgham K, Charneau P, Amoura Z, Gorochoy G. 2020. IgA dominates the early
 456 neutralizing antibody response to SARS-CoV-2. Sci Transl Med
 457 doi:10.1126/scitranslmed.abd2223.
 458

TABLE 1. Diagnostic accuracy of the GenScript cPass surrogate viral neutralization assay to detect neutralizing antibodies among well-characterised specimen panels, according to reference standard used

SOURCE	Number	Reference standard	Cut-off for reference positivity ^a	TP	FP	FN	TN	Sensitivity % (95% CI)	Specificity % (95% CI)
National Microbiology Laboratory panel (Canada)	16 SARS-CoV-2 PCR positive 24 negative for SARS-CoV-2 and positive for related infections	WT PRNT-50	1:20	19	1	0	20	100 (82-100)	95 (76-100)
			1:50	18	2	0	20	100 (81-100)	91 (71-99)
		WT PRNT-90	1:20	7	13	0	20	100 (59-100)	61 (42-77)
			1:50	5	15	0	20	100 (48-100)	57 (39-74)
		PLV ID50	1:50	12	8	1	19	92 (64-100)	70 (50-86)
		PLV ID80	1:50	10	10	0	20	100 (69-100)	67 (47-83)
WHO panel (UK)	3 SARS-CoV-2 positive 2 SARS-CoV-2 negative	WT PRNT-50	1:20	2	1	0	2	100 (16-100)	67 (9-99)
		Live Virus (CPE)	1:20	3	0	1	1	75 (19-99)	100 (3-100)
		VSV-PV	1:20	3	0	0	2	100 (29-100)	100 (16-100)
Blood bank - convalescent plasma donors with longitudinal follow-up ^b	Specimens characterised by anti-S-RBD ELISA and PLV ID50	PLV ID50	1:50	10	2	0	3	100 (69-100)	60 (15-95)
	15 Patients, 6 weeks post-symptom onset								
	Specimens characterised by anti-S-RBD ELISA and PLV ID50	PLV ID50	1:50	8	5	0	1	100 (63-100)	17 (0-64)

	14 Patients, 10 weeks post-symptom onset									
Blood bank - convalescent plasma donors with single timepoint follow-up ^b	Specimens characterised by anti-S-RBD ELISA and PLV ID50	PLV ID50	1:50	24	12	4	10	86 (67-96)	45 (24-68)	
	50 Patients, any time post-symptom onset									
	0-6 weeks post-symptom onset			11	6	1	0	92 (62-100)	0 (0-46)	
	>6 weeks post-symptom onset			13	6	3	10	81 (54-96)	62 (35-85)	
Overall (vs PLV ID50)^c		PLV ID50	1:50	54	27	5	33	92 (81-97)	55 (42-68)	

^a Cut-off used to determine cPass positivity was $\geq 30\%$.

^b From patients meeting public health case definitions of COVID-19, with either NAAT-confirmed SARS CoV-2 infection or an epidemiological link to a known case of COVID-19 (SARS CoV-2 infection).

^c Results from the same PLV ID50 assay were available for all panels except the WHO panel; PLV ID50 assay was used to calculate overall diagnostic accuracy values.

WT PRNT-50 or PRNT-90 denotes neutralization titres required for a 50% or 90% plaque reduction, respectively, using SARS-CoV-2 viral culture; PLV ID50 or PLV ID80 denotes the serum dilution to inhibit 50% or 80% of the infection of 293T-ACE2 cells by recombinant viruses bearing the indicated surface glycoproteins; TP true positive; FP false positive; FN false negative; TN true negative; Anti-S-RBD antibodies against receptor binding domain of SARS-CoV-2 Spike protein; HQ Héma-Québec; WHO World Health Organization; VSV PV Vesicular stomatitis virus pseudovirus; CPE cytopathic effect; NAAT nucleic acid amplification test.

TABLE 2. Diagnostic accuracy of a laboratory-developed IgG anti-RBD ELISA to detect neutralizing antibodies

SOURCE	Number	Reference standard	Cut-off for positivity ^a	TP	FP	FN	TN	Sensitivity	Specificity
National Microbiology Laboratory (Canada)	16 SARS-CoV-2 positive 24 negative for SARS-CoV-2 and positive for related infections	WT PRNT-50	1:20	19	1	0	20	100 (82-100)	95 (76-100)
			1:50	18	2	0	20	100 (81-100)	91 (71-99)
		PLV PRNT-50	1:50	12	8	1	19	92 (64-100)	70 (50-86)

^a Cut-off used to determine cPass positivity was ≥30%.

WT PRNT-50 or PRNT-90 denotes neutralization titres required for a 50% or 90% plaque reduction, respectively, using SARS-CoV-2 viral culture; TP true positive; FP false positive; FN false negative; TN true negative; Anti-S-RBD antibodies against receptor binding domain of SARS-CoV-2 Spike protein; HQ Héma-Québec; WHO World Health Organization; VSV PV Vesicular stomatitis virus pseudovirus; CPE cytopathic effect.

FIGURE LEGENDS

Figure 1. Effect of cut-off values on the diagnostic accuracy of the Genscript cPass SARS-CoV-2 neutralization antibody detection kit.

Panel (A) shows the receiver operating characteristic (ROC) curve, with different cPass cutoffs. Panel (B) details results and estimates of sensitivity and specificity for different %inhibition of RBD-ACE2 binding cutoffs for cPass positivity. The reference standard used is PLV PRNT 50 at a titre of $\geq 1:50$. AUC denotes Area Under the ROC Curve; TP true positive; FP false positive; FN false negative; TN true negative.

Figure 2. Effect of serial dilution on the accuracy for detecting sera with positive PRNT90 titres.

Serial dilution of the 16 primary specimens with WT PRNT 50 titres $\geq 1:20$ was performed to establish a dilution that increased specificity for detecting those with WT PRNT 90 titres $\geq 1:20$. Panel (A) shows individual data points according to dilution and WT PRNT 90 status (positive $\geq 1:20$). Box plots depict the median and interquartile range. Panel (B) details results and estimates of sensitivity and specificity for serial dilution factor. All dilution factors are additional to the 10X dilution required in the manufacturer's instructions. WT PRNT 90 denotes neutralization titres required for a 90% plaque reduction using SARS-CoV-2 viral culture; TP true positive; FP false positive; FN false negative; TN true negative.

Figure 3. Correlation of the Genscript cPass assay with anti-S-RBD ELISA.

Scatterplots and Pearson correlation coefficient for results obtained with cPass compared to those obtained using laboratory-developed ELISA detecting anti-RBD IgG, IgM, and IgA (Panels A, B, C, respectively). The vertical dashed line depicts the manufacturer's recommended cut-off for cPass positivity.

508

509 **Figure 4.** Change of signal over time for Genscript cPass and anti-RBD ELISA.

510 Spaghetti plot of results obtained with cPass (panel A) and optical densities of laboratory-

511 developed ELISA detecting anti-RBD IgG, IgM, and IgA (panels B, C, D, respectively)

512 among specimens collected at a known interval from SARS-CoV-2 diagnosis. Horizontal

513 lines indicate paired specimens form the same individual. P values are calculated via the


514 Wilcoxon signed rank test, and values <0.05 are designated with an Asterix. In all panels, red

515 dots denote specimens with positive cPass results, and blue dots specimens with negative

516 cPass results.

517


Figure 1. Effect of cut-off values on the diagnostic accuracy of the Genscript cPass SARS-CoV-2 neutralization antibody detection kit.



Panel (A) shows the receiver operating characteristic (ROC) curve, with different cPass cutoffs. Panel (B) details results and estimates of sensitivity and specificity for different %inhibition of RBD-ACE2 binding cutoffs for cPass positivity. The reference standard used is PLV PRNT 50 at a titre of $\geq 1:50$.


AUC denotes Area Under the ROC Curve; TP true positive; FP false positive; FN false negative; TN true negative.

Figure 2. Effect of serial dilution on the accuracy for detecting sera with positive PRNT90 titres.




Serial dilution of the 16 primary specimens with WT PRNT 50 titres $\geq 1:20$ was performed to establish a dilution that increased specificity for detecting those with WT PRNT 90 titres $\geq 1:20$. Panel (A) shows individual data points according to dilution and WT PRNT 90 status (positive $\geq 1:20$). Box plots depict the median and interquartile range. Panel (B) details results and estimates of sensitivity and specificity for serial dilution factor. All dilution factors are additional to the 10X dilution required in the manufacturer's instructions. WT PRNT 90 denotes neutralization titres required for a 90% plaque reduction using SARS-CoV-2 viral culture; TP true positive; FP false positive; FN false negative; TN true negative.

Figure 3. Correlation of the Genscript cPass assay with anti-S-RBD ELISA.




Scatterplots and Pearson correlation coefficient for results obtained with cPass compared to those obtained using laboratory-developed ELISA detecting anti-RBD IgG, IgM, and IgA (Panels A, B, C, respectively). The vertical dashed line depicts the manufacturer's recommended cut-off for cPass positivity.

Figure 4. Change of signal over time for Genscript cPass and anti-RBD ELISA.




Spaghetti plot of results obtained with cPass (panel A) and optical densities of laboratory-developed ELISA detecting anti-RBD IgG, IgM, and IgA (panels B, C, D, respectively) among specimens collected at a known interval from SARS-CoV-2 diagnosis. Horizontal lines indicate paired specimens from the same individual. P values are calculated via the Wilcoxon signed rank test, and values <0.05 are designated with an Asterix. In all panels, red dots denote specimens with positive cPass results, and blue dots specimens with negative cPass results.



A

Threshold % inhibition for positivity	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
20%	43	25	3	9	93.5 (82.1-98.6)	26.5 (12.9-44.4)
30%	42	20	4	14	91.3 (79.2-97.6)	41.2 (24.6-59.3)
40%	40	16	6	18	86.9 (73.7-95.1)	52.9 (35.1-70.2)
50%	37	10	9	24	80.4 (66.1-90.6)	70.6 (52.5-84.9)
60%	31	6	15	28	67.4 (52.0-80.5)	82.3 ((65.5-93.2)


B




A

Dilution Factor	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
1X	7	8	0	1	100 (59-100)	11 (0-48)
10X	7	3	0	6	100 (59-100)	67 (30-93)
50X	6	0	1	9	86 (42-100)	100 (66-100)
100X	4	0	3	9	57 (18-90)	100 (66-100)


B



A




B




C


A



B



C



D

